Moderna (MRNA) Accounts Payables (2017 - 2026)

Moderna has reported Accounts Payables for 10 years, with the latest figure at $167.0 million in Q2 2026.

• Accounts Payables for Q2 2026 came in at $167.0 million, down 4.57% year-over-year; the trailing twelve-month figure through Jun 2026 was $167.0 million (down 4.57% YoY), and the FY2025 annual result was $317.0 million, down 21.73% from the prior year.
• Accounts Payables climbed to $167.0 million in Q2 2026, from $161.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $520.0 million in Q4 2023 and troughed at $161.0 million in Q1 2026.
• A 5-year average of $303.5 million and a median of $294.5 million in 2023 frame the typical range for Accounts Payables.
• The widest annual swing landed in 2022, when Accounts Payables jumped 2387.5%; it then slumped 52.96% in 2024.
• A 5-year view of Accounts Payables shows it stood at $487.0 million in 2022, then increased by 6.78% to $520.0 million in 2023, then decreased by 22.12% to $405.0 million in 2024, then declined by 21.73% to $317.0 million in 2025, then plunged by 47.32% to $167.0 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $167.0 million in Q2 2026, $161.0 million in Q1 2026, and $317.0 million in Q4 2025.